0001209191-22-025469.txt : 20220422 0001209191-22-025469.hdr.sgml : 20220422 20220422200415 ACCESSION NUMBER: 0001209191-22-025469 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220420 FILED AS OF DATE: 20220422 DATE AS OF CHANGE: 20220422 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Valliant John CENTRAL INDEX KEY: 0001813574 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39344 FILM NUMBER: 22847099 MAIL ADDRESS: STREET 1: FUSION PHARMACEUTICALS INC. STREET 2: 270 LONGWOOD ROAD SOUTH CITY: HAMILTON STATE: A6 ZIP: L8P 0A6 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fusion Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001805890 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 270 LONGWOOD ROAD SOUTH CITY: HAMILTON STATE: A6 ZIP: L8P 0A6 BUSINESS PHONE: 289-799-0891 MAIL ADDRESS: STREET 1: 270 LONGWOOD ROAD SOUTH CITY: HAMILTON STATE: A6 ZIP: L8P 0A6 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-20 0 0001805890 Fusion Pharmaceuticals Inc. FUSN 0001813574 Valliant John C/O FUSION PHARMACEUTICALS, INC. 2 INTERNATIONAL PLACE, SUITE 2310 BOSTON MA 02110 1 1 0 0 Chief Executive Officer Common Stock 2022-04-20 4 S 0 367 6.02 D 327763 D Common Stock 2022-04-21 4 S 0 922 6.01 D 326841 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.02 to $6.03 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.00 to $6.05 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. /s/Maria Stahl as Attorney-in-Fact for John Valliant 2022-04-22